Tempest director John Yee reports no TPST share ownership
Tempest Therapeutics, Inc. director John D. Yee filed an initial Form 3, which is the required statement of beneficial ownership for new insiders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tempest Therapeutics, Inc. director John D. Yee filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing shows no reported transactions, derivative positions, or holding entries at this time.
Key Terms
Form 3 regulatory
beneficial ownership regulatory
reporting person regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does John D. Yee's Form 3 filing mean for TPST investors?
Does the TPST Form 3 for John D. Yee show any stock purchases or sales?
Are there any options or derivatives reported for John D. Yee in TPST's Form 3?
What insider role does John D. Yee have at Tempest Therapeutics (TPST)?
Does the TPST Form 3 include any footnote disclosures for John D. Yee?
AI-generated analysis. How Rhea-AI works. Not financial advice.